MedTrace Logo

Safety Study of BLS-M22 in Healthy Volunteers

NCT03789734 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2021-04-22

No results posted yet for this study

Summary

BLS-M22 is being developed as an anti-myostatin agent for the treatment of Duchenne Muscular Dystrophy (Muscular Dystrophy). A total of 37 subjects participated in this study to confirm the safety of BLS-M22.

Conditions

  • Muscular Dystrophy, Duchenne

Interventions

BIOLOGICAL

BLS-M22

BLS-M22 250mg/capsule

OTHER

Placebo

BLS-M22 placebo 250mg/capsule

Sponsors & Collaborators

  • BioLeaders Corporation

    lead INDUSTRY

Principal Investigators

  • Doyoung Lee, PhD · BioLeaders corp

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-04
Primary Completion
2020-04-23
Completion
2020-11-27

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03789734 on ClinicalTrials.gov